Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cerivastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 2/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | PDE4A | P27815 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cerivastatin SCHEMBL15263415 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL3946004 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL31517662 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL28019013 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL41887 | 1.00 | HMGCR (0.84) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL19518120 | 0.97 | HMGCR (0.80) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| Cerivastatin SCHEMBL2900117 | 0.97 | HMGCR (0.90) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL6633443 | 0.94 | HMGCR (0.75) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL15686549 | 0.91 | HMGCR (0.86) | HMGCRESR1CHRM1TBXA2RPDE4A | |
| SCHEMBL13890391 | 0.91 | HMGCR (0.86) | HMGCRESR1CHRM1TBXA2RPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9609 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-12208071-B2 | Glucagon receptor antagonists | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2025-01-28 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-3193824-B1 | A COMPOSITION FOR USE IN TREATING HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA VIA PHYSIOLOGICALLY SYNTHESISED GLUTATHIONE | THE PROIMMUNE COMPANY LLC (US) | 2023-07-05 | — | — | EP | claimed |
| EP-1519715-B1 | NANOPARTICULATE FIBRATE FORMULATIONS | ALKERMES PHARMA IRELAND LTD (IE) | 2023-02-22 | — | — | EP | claimed |
| EP-3585775-B1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2022-04-06 | — | — | EP | claimed |
| US-20210121422-A1 | GLUCAGON RECEPTOR ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-04-29 | — | — | US | claimed |
| EP-3787631-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | Emory University (US) | 2021-03-10 | — | — | EP | claimed |
| WO-1997038694-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | claimed |
| WO-1997028149-A1 | METHOD FOR RAISING HDL CHOLESTEROL LEVELS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | claimed |
| EP-0782451-A1 | COMBINATION OF A CHOLESTEROL ABSORPTION INHIBITOR AND A CHOLESTEROL SYNTHESIS INHIBITOR | PFIZER INC. (US) | 1997-07-09 | — | — | EP | claimed |
| WO-1997016184-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION | WARNER-LAMBERT COMPANY (US) | 1997-05-09 | — | — | WO | claimed |
| CN-1148492-A | Treatment for arteriosclerosis and vitiligoidea | SANKYO CO (JP) | 1997-04-30 | — | — | CN | claimed |
| EP-0753298-A1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO COMPANY LIMITED (JP) | 1997-01-15 | — | — | EP | claimed |
| WO-1996009827-A2 | COMBINATION OF A CHOLESTEROL ABSORPTION INHIBITOR AND A CHOLESTEROL SYNTHESIS INHIBITOR | PFIZER INC. (US) | 1996-04-04 | — | — | WO | claimed |
| EP-0698609-A1 | Alpha-phosphorus substituted sulfinate derivatives as squalene synthetase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-02-28 | — | — | EP | claimed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |